Time to Deterioration of Patient-Reported Outcomes in Cancer Trials
Author Information
Author(s): Cocks Kim, King-Kallimanis Bellinda L., Sims Joel, Worthy Gill, Stein Julia, Ayala–Nunes Lara, Achra Monika, Cui Zhanglin Lin, Payakachat Nalin
Primary Institution: Adelphi Values Ltd
Hypothesis
How are time to deterioration (TTD) endpoints defined and used in oncology clinical trials?
Conclusion
The definition of TTD endpoints varies significantly across trials, impacting their utility and interpretation.
Supporting Evidence
- Seventy RCTs were included covering 849 individual TTD endpoints.
- Most trials (71%) were for people with advanced cancer.
- Full definitions of TTD endpoints were often missing.
Takeaway
This study looked at how doctors measure when cancer patients start to feel worse during treatment, and found that different studies use different ways to measure this.
Methodology
A targeted literature review of articles published between 2017 and 2022 was performed to collate TTD endpoints reported in oncology randomized controlled trials.
Potential Biases
Potential bias due to the exclusion of non-English publications and conference abstracts.
Limitations
The review may not have included all relevant trials due to the ranking process used for selecting articles.
Participant Demographics
The trials included various cancer types, primarily lung, breast, and prostate cancers, with most participants having advanced cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website